If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Guys come on! (medium/long term) Some of you have missed some very important clues in the posts last night. I am not going to put them on here as they will be wasted on the 10 minute holders. There was a reason to post them. Look up Conduit Pharmaceuticals and their approach, strengths and past deals, then link it back to us. Again ask why they were 4p a share? Do you think CP want 4p!! Keep going and you will get it. Oh and thats just one clue. The rest are in the other posts. You can get news at any time on something else!!
Personally not interested in the price at the moment.
Dr Freda Lewis-Hall Proposed Chair
During her 35-year career in medicine, Dr. Freda Lewis-Hall served as Pfizer, Inc.’s Chief Medical Officer and Executive Vice President until the end of 2018 and as Chief Patient Officer and Executive Vice President during 2019. Before joining Pfizer, Freda held senior leadership positions in medical affairs and product development with Vertex, Bristol-Myers Squibb, Pharmacia and Eli Lilly and Company.
Dr. Freda Lewis-Hall has been on the frontlines of healthcare as a clinician, a researcher, and a leader in the biopharmaceuticals and life sciences industries. The common thread throughout has been her passion to advocate for health equity and improved outcomes for all patients. Dr. Lewis-Hall appears regularly on health-related television programs in major global markets, including CBS-syndicated shows such as The Doctors and Dr. Phil. She also shares health and medical information through GetHealthyStayHealthy.com.
Prior to joining the biopharmaceutical industry, she served as vice chairperson and associate professor in the Department of Psychiatry at Howard University College of Medicine and was an advisor to the National Institute of Mental Health. Dr. Lewis-Hall served on the board of directors of SpringWorks Therapeutics, a biopharmaceutical company which licensed four compounds initially from Pfizer which currently has a Market Capitalisation of $3.08Bn (Jan 2022), in collaboration with UK-charity LifeArc.
These guys recently took last month 8.98% of CIZ at a price of 4p. They will be receiving subject to shareholder agreement another 22m shares at 4p to take their holding to 15.64% of any enlarged share capital. Who are they? What could they do for CIZ?
Prior to joining the Charity St. George Street Capital as Chief Executive Officer and a trustee, David held senior leadership positions at Senior Vice President or CEO level in international R&D healthcare companies and Charities with responsibility for the strategic leadership of these organisations. David’s past roles include joint worldwide head of chemistry for Zeneca agrochemicals, Vice President of Glaxo Smith Kline Pharmaceuticals and Senior Vice President of Millennium Pharmaceuticals which, at the time, was the third largest Biotech company in the world. At St. George Street Capital he successfully led a £7m funding round to fund a Covid-19 clinical trial programme on an asset that was licensed out from Astra Zeneca Pharmaceuticals.
David built an extensive network of connections in the technology transfer and commercialisation sector of UK University technology transfer offices and represented the healthcare sector of the UK at International Conferences in Europe and the Far East and trade missions to Japan and China. During these missions he met with the ministers of health for both countries and even the current and previous presidents of China.
Whilst at LifeArc David worked closely with Dr Freda Lewis-Hall to create the highly innovative and hugely successful company Springworks which currently has a Market Capitalisation of $3.08Bn (Jan 2022). David left LifeArc having steered the charity to Endowment status funding with a cash balance of $1.4Bn.
David also worked extensively as an entrepreneur having now started or been involved with the creation or funding of 10 new life science companies here in the UK. Four of these successfully exited via trade sales, one was listed on the AIM market and one was listed on the London Stock Exchange. He has also served as a non-Executive director/Chairman in a range of Biotech and healthcare technology companies both here in the UK and internationally.
(more to follow....)
https://www.who.int/news-room/fact-sheets/detail/cancer
"Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020 (1). The most common in 2020 (in terms of new cases of cancer) were:"
"lung (2.21 million cases)"
The most common causes of cancer death in 2020 were:
lung (1.80 million deaths);
colon and rectum (916 000 deaths);
liver (830 000 deaths);
stomach (769 000 deaths); and
breast (685 000 deaths).
Early detection
Cancer mortality is reduced when cases are detected and treated early. There are two components of early detection: early diagnosis and screening.
Early diagnosis
When identified early, cancer is more likely to respond to treatment and can result in a greater probability of survival with less morbidity, as well as less expensive treatment. Significant improvements can be made in the lives of cancer patients by detecting cancer early and avoiding delays in care.
Early diagnosis consists of three components:
being aware of the symptoms of different forms of cancer and of the importance of seeking medical advice when abnormal findings are observed;
access to clinical evaluation and diagnostic services; and
timely referral to treatment services.
Early diagnosis of symptomatic cancers is relevant in all settings and the majority of cancers. Cancer programmes should be designed to reduce delays in, and barriers to, diagnosis, treatment and supportive care.
Given CIZ have signed a full commercial agreement for early lung cancer diagnostic tests in China, its surprising to see that China are actually rated 16th highest by the American Institute for Cancer Research and World Cancer Research Fund.
https://www.wcrf.org/dietandcancer/lung-cancer-statistics/
Lung cancer rates: both sexes
Rank Country Age-standardised rate per 100,000
1 Hungary 56.7
2 Serbia 49.8
3 New Caledonia (France) 42.3
4 Greece 40.5
5 French Polynesia 39.8
6 Montenegro 39.7
7 Belgium 39.0
8 Guam 37.9
9 Turkey 36.9
10 Denmark 36.6
11 Poland 36.5
12 North Korea 36.2
13= Bosnia & Herzegovina 36.1
13= France (metropolitan) 36.1
15 Samoa 35.4
16= China 35.1
16= US 35.1
18 Macedonia 34.1
19= Germany 33.7
19= Ireland 33.7
21 Netherlands 33.3
22 Slovenia 32.9
23 Croatia 32.5
24 UK 32.5
25 Slovakia 31.2
Lung cancer rates in men
Rank Country Age-standardised rate per 100,000
1 Hungary 77.4
2 Serbia 71.6
3 Turkey 70.6
4 Greece 67.8
5 Montenegro 62.9
6 Bosnia & Herzegovina 62.4
7 New Caledonia (France) 59.9
8 Armenia 58.5
9= French Polynesia 55.7
9= Macedonia 55.7
11 Belarus 54.5
12 Slovakia 54.3
13 Guam 53.7
14 Poland 52.7
15 Lithuania 52.6
16 Belgium 52.2
17 Latvia 51.8
18 Estonia 51.4
19 France (metropolitan) 51.3
20 Croatia 50.9
21 Romania 50.7
22 Moldova 50.5
23 Bulgaria 50.1
24 Russia 48.2
25 North Korea 48.1
Any traders this will not interest you and wish you well on your trades regardless. Any serial rooblers desperate to lose money by chopping and changing every 5 mins, (roobler, ADV "I bet this turns around quickly", Jan 19 2022), these links are not for you either.
Medium/Long term holders I hope this gives some indication on why CIZ is a must for trying to help in the area of lung cancer.
Abstract
China is in the midst of a lung cancer epidemic on an unprecedented scale. In 2015, there were an estimated 733,000 new lung cancer cases (17% of total cancer incidence) and 610,000 deaths (21.7% of total cancer mortality) in China. Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality in China. Tobacco smoke exposure is the primary factor driving current lung cancer trends. In 2015, smoking prevalence was 27.7% (52.1% among men and 2.7% among women). China has taken substantial steps to control tobacco use in recent years, including 19 cities implementing comprehensive smoke free laws and expansion of cessation services. However, significant challenges remain in order to meet the 2030 Healthy China goal of reducing smoking prevalence to 20%. In particular, ongoing attention is needed to continuing to control secondhand smoke exposure, to further enhance smoking cessation services, and to address novel alternative nicotine delivery devices (ANDS).
https://tlcr.amegroups.com/article/view/28292
Regarding mortality, it was estimated that about 630,500 patients with lung cancer died in 2015, which is equivalent to an average of over 1700 deaths each day. Lung cancer accounted for 27% of the mortality of all sites combined, and the age-standardized mortality rate was estimated to be 28.02 per 100,000 in the People’s Republic of China in 2015. The numbers of lung cancer deaths were 433,200 and 197,300, with age-standardized rates for lung cancer mortality of 40.11 and 16.54 per 100,000 for the male and female populations, respectively. The rural areas had relatively higher age-standardized rates of lung cancer mortality (40.41 per 100,000) for male individuals than the urban areas (39.85 per 100,000).
https://www.jto.org/article/S1556-0864(20)30375-0/fulltext
Take them, ignore them, do what you will with them.
I added up the total holdings of the first 17 holders that came up on the share register list. I am not going to name them out of respect. They range from holdings worth £1.2m down to £100k.
Out of those 17 holders, 9 were Corporate Holders, 1 Venture Capitalist, and 6 Individual Investors. What was also interesting was they had a combined holding worth, £5.3m.
The current Market Cap of 278,447,788m shares x 2.5p (current price as at writing) is £6.96m. So anyone looking for stability needs to realise that these holders practically are 76% of that market cap! This is a very strong indicator and strong base for the share.
55.69% of all shares are now accounted for. That is 154,982,059 shares. This means 123,465,729 shares are either changing hands at all times or with nominee accounts not accounted for on the registrar.
45,105,941 have been sold from those on the register since 06.12.21, from 7 different accounts, of which 5 of those are no longer holders. This was made up of 2 Corporate Holders, 3 Individual Investors, with 1 Corporate Holder, and one Venture Capitalist reducing holdings.
44 new Individual Investors and 6 Corporate Holders have entered the share register since the 15.01.22 with buying of 32,202,092 Total between them.
The exercise was to see if it was any one of the top holders were selling out or buying as we are not possession of any Tr1s. It looks to me that those trades of 6.3m or 5.3m recently are off register, and given the stability at the top is not much to worry about. What I do believe is happening in my opinion is that given the potential news, the market has gone on an accumulation phase to relieve the weak holders by dropping the price and leaving them to panic out of the holding and be replaced by stronger holders before the next set of news.
Time stamps I see are:
15:07:28 2.6p 6.3m
15:09:13 2.6p 6.3m
15:10:39 2.6p 6.3m
All trades done with bid and ask at 2.5-2.6p
Those 2 x 6.3m would add up to 4.52% of the total company voting rights. There are only three holders who are capable of selling that amount. Yorkshire Cancer Research, which I doubt, as that would defeat their presence and they are the biggest holders. Dawn Coverley who actually started the company and that would also make this a farce, and finally our new holders, which would be possible as they were given the stock for free, and it makes close to 50% of their current holding.
So the only deducement one can make is that we do have a potential buyer as the trades went through at ask full price, unless both 6.3m were seperate entities. I would also deduce that we should be then getting a new TR1 very soon, one way or the other.
mcadder as you may or may not know I have been in CIZ since 2019 in its various forms and still here. So no offence intended.
Fact 1 There has been no RNS to confirm any further sellers since the last RNSs
Fact 2 The only facts are the news coming out of the company.
You said "just imagine what would happen" and "you can imagine" and then said its not ramping its fact. Its not my friend its your imagination and your scenario "say for argument sake" has not actually happened. What is happening is the price is cheaper than last week and so therefore one will need to work out for themselves from their own risk tolerance whether that offers a good deal or not. Its a numbers game and the company has clearly put in the last China related RNS what those numbers could turn out as. That is why I personally hold, and not because so and so sold last week, or so and so bought or "just imagine." Imagination is very dangerous if not used wisely, and in these times imagination is the last thing we should rely on.
I will give you this much, its a good opportunity.
https://text.123docz.net/document/5952845-expression-of-ciz1b-in-patients-with-non-small-cell-lung-cancer.htm
Journal of military pharmaco-medicine n08-2018 disease status, suggesting that Ciz1b plays an important role in the development of lung cancer. The results also suggest that Ciz1b gene may be used as a biomarker for diagnosis and prognosis of lung cancer [5]. The study showed that Ciz1b levels help diagnose cancer patients with an accuracy threshold of 98% for patients with NSCLC and controls (AUC = 0.96). When comparing patients with NSCLC in stage I with asymptomatic smokers, or those with benign pulmonary lymph nodes, the AUC reached 0.913, and 0.905, respectively. In this study, we also analyzed the diagnostic potential of Ciz1b for patients with NSCLC and the results showed that Ciz1b was capable of detecting patients with NSCLC (AUC=0.602). Therefore, determining the presence of Ciz1b in the serum of high-risk groups is an effective non-invasive method for diagnosing, screening and predicting lung cancer. CONCLUSION Increased Ci1zb mRNA expression in patients with NSCLC was observed compared to healthy individuals. Citzb mRNA expression levels were associated with tumor cell differentiation and correlated with liver enzyme levels.
Ci1zb plays an important role in lung cancer development and has the potential as a biomarker for diagnosis and prognosis of lung cancer.
Ciz1b Variant as a Surrogate Marker in Surveillance of Lung Cancer Recurrence
https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A3129
'Conclusion: Serial plasma Ciz1b variant expression may have a tremendous potential to be used as a surrogate marker in surveillance of lung cancer recurrence, Ciz1b variant may serve as a unique noninvasive biological test for diagnosis and disease monitoring in lung cancer.'
2017 Apr
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441127/
Objectives
Non-invasive tests for early detection of lung cancer are an important unmet clinical need. CIZ1b plasma biomarker can discriminate stage 1 lung cancer from within high-risk groups with clinically useful accuracy, with ROC AUCs in excess of 0.9 for two independent retrospective cohorts, and could therefore meet this need.
Conclusions
Unexpected and unusual molecular structure of CIZ1b in native plasma has complicated immunoassay design, and delayed translation of this promising biomarker. However, CIZ1b can now be measured using a high-throughput, hospital-friendly sandwich ELISA format, overcoming an important barrier to further clinical development and application of this blood test for early stage lung cancer.
Before this gets lost in the minute by minute commentary, I am reposting this again.
This is probably one of the most important videos long term holders should watch. Posted on 11th Feb 2022 (10 days ago), and at last count only had 14 watches 10 as of last night). It will certainly rack up a lot more with time.
https://www.youtube.com/watch?v=MOswBpjrCQA&ab_channel=UoYCommercialisationTeam
https://www.youtube.com/watch?v=MOswBpjrCQA&ab_channel=UoYCommercialisationTeam
InvestingGenius
Could you post in what capacity the proposed directors are working with GW Pharmaceuticals as I am struggling on this? What are their current roles at GW Pharma?
I do not own any shares OCTP but its on my watch list.
Great news that they held and not sold. This will make the job of buying even harder for others as there is only 90m free float available (see post from em earlier in the week) and those have probably very few floating around. Given the next news as and when will rerate this. CIZ have confirmed to me they will update the website.
Jigger_1
Yes the information my friend is off the CIZ website, but the date was the first thing I looked for and realising it was out of date I used the various recent holding updates and today's total voting right RNS to update all calculations. I have made the amendments to the holdings so they are up to scratch to my knowledge and calculations. The Finance Yorkshire holding has been adjusted accordingly to take into account their recent sales. I have added Conduit's holding into the list as well.
BTW your recent posts have been very helpful. Nice one will use in my own researching.
Jim Nominees
46,590,287
16.73
Yorkshire Cancer Research
32,382,330
11.62
Finance Yorkshire Seedcorn Fund
7,437,410
2.67
Bank of New York Nominees
17,534,371
6.29
Roy Nominees
15,195,532
5.45
Dawn Coverley
13,359,042*
4.79
University of Sheffield
11,128,058
3.99
University of Leeds
11,128,058
3.99
University of York
8,195,045
2.94
Conduit Pharmaceuticals
25,000,000
8.98%
There are 278,447,788 shares (Total Voting Rights as of 16.02.2022)
67.36% is held by the holders above of which two are no longer significant holders, above 3%. Conduit Pharmaceuticals is the new name in the list. From the above list the total holding is 187,562,429.
32.64% or 90,885,358 are free float to the market right now.
PLEASE DO NOT PRINT OR CAVE INTO DEMAND FROM OTHERS TO PRINT YOUR HOLDINGS HERE. I WOULD NOT ASK ANYONE THEIR BANK PIN NUMBER OR YOUR CARDS AT THE TABLE. VARIOUS PARTIES HAVE MOTIVES. NEVER FORGET THAT ESPECIALLY THE NEWBIES AND THOSE WHO THINK THEY SHOULD DO IT AS ITS ONLY A BIT OF FUN. TAKE IT FROM SOMEONE WITH EXPERIENCE. DO NOT REVEAL YOUR HOLDINGS UNLESS ITS WITHIN THE LIST ABOVE.
Honestly Riseoftheporper? Short term above 4p. Long term, given that the deal of £300m per annum to CIZ cost free IF and that still an IF, is signed, that alone adds £1.08 to the bottom line per annum!.So long term I don't have a value as I will not need to ever sell this. This is if you were asking me my friend? Its a case of adding as and when you can which would be the better option.
Been here since the PSL days and been through the pain of the suspension etc like a few good people here. Now its finally paid off holding.